Unió Europea - islandès - EMA (European Medicines Agency)

eli lilly nederland b.v. - raloxifen hýdróklóríð - beinþynning, eftir tíðahvörf - hormón kynlíf og stillum kynfæri - optruma er ætlað til meðferðar og fyrirbyggingar beinþynningar hjá konum eftir tíðahvörf. veruleg lækkun á tíðni beinbrota, en ekki brot á mjöðmum, hefur verið sýnt fram á. Þegar ákvörðun val á raloxifen eða öðrum meðferð, þar á meðal estrógenum, fyrir einstaka tíðahvörf kona, skal íhuga að tíðahvörf einkenni, áhrif á legi og barn vefja, og hjarta áhættu og fríðindi (sjá kafla 5.

Unió Europea - islandès - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - ristruflanir - Þvaglát - meðferð við ristruflunum hjá fullorðnum körlum. til þess að tadalafil sé skilvirk, þarf kynlíf örvun. tadalafil lilly er ekki ætlað að nota af konum. meðferð einkenni á góðkynja stækkunar í fullorðnum körlum.

Unió Europea - islandès - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - brjóstakrabbamein - Æxlishemjandi lyf - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Unió Europea - islandès - EMA (European Medicines Agency)

eli lilly nederland b.v. - galcanezumab - mígreni kvilla - analgesics, galcanezumab - emgality er ætlað til að fyrirbyggja mígreni í fullorðnir sem hafa minnsta kosti 4 mígreni daga á mánuði.

Unió Europea - islandès - EMA (European Medicines Agency)

eli lilly nederland b.v. - glúkagon - sykursýki - brisi hormón, glycogenolytic hormón - baqsimi er ætlað fyrir meðferð alvarlega blóðsykursfall í fullorðnir, unglingar, og börn sem eru 4 ár og yfir með sykursýki.

Unió Europea - islandès - EMA (European Medicines Agency)

eli lilly nederland b.v. - insúlín lispró - sykursýki - lyf notuð við sykursýki - meðferð sykursýki hjá fullorðnum, unglingum og börnum á aldrinum 1 ára og eldri. meðferð sykursýki hjá fullorðnum.

Unió Europea - islandès - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - Æxlishemjandi lyf - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Unió Europea - islandès - EMA (European Medicines Agency)

eli lilly nederland b.v. - tirzepatide - sykursýki, tegund 2 - lyf notuð við sykursýki - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 og 5.

Unió Europea - islandès - EMA (European Medicines Agency)

eli lilly nederland b.v. - lasmiditan succinate - mígreni kvilla - verkjalyf - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Unió Europea - islandès - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - ristilbólga, þvagsýrugigt - Ónæmisbælandi lyf - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.